profit from every $100 of sales.
$0$100
Climb Bio
$10.36-4.69% today
+442.4% in 1 year
1-year low $1.641-year high $17.84
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Climb Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$59.9 million of profit last year.
SalesProfit
Climb Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Climb Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Climb Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -45 | -40 | -30 | -68 | |
| -45 | -40 | -30 | -68 | |
| -45 | -35 | -74 | -60 | |
| -1.72 | -1.30 | -1.53 | -0.88 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 135 | 110 | 217 | 168 |
| Cash | 44 | 93 | 87 | 36 |
| Total debt | 0 | 0 | 1 | 1 |
| Total liabilities | 6 | 3 | 5 | 7 |
| 129 | 108 | 212 | 160 | |
| 26 | 27 | 48 | 48 | |
| -27.6% | -29.5% | -11.3% | -33.3% | |
| -35.2% | -32.6% | -34.9% | -37.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -37 | -21 | -16 | -54 | |
| – | – | – | 0 | |
| -37 | -21 | -16 | -55 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 13 | 6 | 8 |
Valuation
- –
- –
- –
- 5.4×
- –
- –
- –
- -9.0%
- -9.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -40.4%
- -33.6%
- -31.5%
- -34.6%
- -40.5%
- –
Growth
- –
- –
- −250.5%
- –
- +53.4%
Financial health
- 0.1×
- 0.00
- 0.3%
- –
- 27.86
- 27.86
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 946
Bottom 21%of 871
Bottom 13%of 986
What analysts expect
- Average price target
- $17.75
- Range
- $11.00 – $25.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.20 | -0.26 | +23.1% |
| Mar 5, 2026 | -0.26 | -0.20 | −30.0% |
| Nov 6, 2025 | -0.19 | -0.16 | −18.8% |
| Aug 12, 2025 | -0.13 | -0.19 | +31.6% |
| May 14, 2025 | -0.31 | -0.15 | −106.7% |
| Mar 25, 2025 | -0.13 | -0.15 | +13.3% |
| Nov 12, 2024 | -0.13 | – | – |
| Aug 14, 2024 | -1.81 | – | – |
News
Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields ClimbYahoo Finance · Nov 13, 2026Ron Baron Says Tesla (TSLA) Could Climb Within a Decade. Ark’s Model Leans on RobotaxisYahoo Finance · Nov 12, 2026Apple’s inventory surges 154% as memory chip costs climbYahoo Finance · Nov 2, 2026Microsoft's Windows sales fell 22% as PC prices climbYahoo Finance · Oct 30, 2026Climb Global Solutions Non-GAAP EPS of $0.43 beats by $0.05, revenue of $220.3M beats by $39.32MSeeking Alpha · Oct 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
40No pass
Philip Fisher
33No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
28No pass
Questions about Climb Bio
Is Climb Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Climb Bio AI analysis
What does Climb Bio do?
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It is in Biotechnology.
Does Climb Bio pay a dividend?
No. Climb Bio does not pay a dividend at the moment.
Is Climb Bio stock halal?
Yes. Climb Bio passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Climb Bio stock done over the past year?
Up 442.4% over the past twelve months, to $10.36. It traded between $1.64 and $17.84 and is 41.9% below its high.
Who are Climb Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Climb Bio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.